Welcome to our dedicated page for Cardio Diagnostics Holdings SEC filings (Ticker: CDIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including annual and quarterly reports, current reports, and proxy materials. As an artificial intelligence-powered precision cardiovascular medicine company listed on The Nasdaq Stock Market LLC, Cardio Diagnostics uses these filings to report on its operations, governance, capital structure, and key corporate events.
Through documents such as Form 10-K and Form 10-Q, investors can review detailed information about the company’s business, including its focus on AI-driven Integrated Genetic-Epigenetic technology for cardiovascular disease, the development and commercialization of its Epi+Gen CHD and PrecisionCHD tests, and risk factors relevant to its operations. Form 8-K current reports, such as the filing describing the company’s regaining compliance with Nasdaq’s minimum bid price requirement, provide timely updates on material events, corporate actions, and listing status.
Proxy statements filed on Schedule 14A offer insight into Cardio Diagnostics’ corporate governance, including the election of directors, proposals related to future share issuances under Nasdaq rules, and the ratification of its independent registered public accounting firm. These documents also describe how stockholders can participate in virtual annual meetings and vote on key matters.
On Stock Titan, Cardio Diagnostics filings are updated in near real time from the SEC’s EDGAR system and are accompanied by AI-powered summaries that highlight important sections and explain complex disclosures in clear language. Users can quickly locate information about capital markets activity, such as approvals for potential future share issuances, and monitor governance decisions documented in proxy materials. For investors analyzing CDIO, this page serves as a centralized resource for reviewing the company’s regulatory history and understanding how its precision cardiovascular medicine strategy is reflected in formal SEC reporting.
Cardio Diagnostics Holdings, Inc. will hold its 2025 annual meeting virtually on October 15, 2025 at 10:00 a.m. Central Time for holders of record as of August 25, 2025. As of the record date the company reported 1,763,129 shares of common stock outstanding. The board recommends voting FOR three proposals: (1) election of seven director nominees for one-year terms; (2) approval to issue shares and/or convertible/exercisable securities in one or more non-public transactions equal to 20% or more of outstanding common stock under Nasdaq Rule 5635(d); and (3) ratification of Prager Metis CPA's LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The proxy discloses parameters for the 2025 Issuance Proposal: a maximum of 1,666,666 shares (post 1-for-30 reverse split), a maximum aggregate dollar amount of $10.0 million, a maximum discount to market of 25%, and an intended issuance timeframe not to exceed three months from stockholder approval (with potential Nasdaq approval to extend to six months).
Cardio Diagnostics Holdings, Inc. is soliciting proxies for a virtual Annual Meeting on October 15, 2025 where stockholders will vote on three items: election of seven director nominees (including the CEO and CMO, both co‑founders), ratification of Prager Metis CPA's LLC as the company’s independent registered public accounting firm, and approval to permit future non‑public issuances of Common Stock or convertible/exercisable securities equal to 20% or more of outstanding shares in accordance with Nasdaq Rule 5635(d).
The 2025 Issuance Proposal requests authorization to issue up to 1,666,666 shares (post 1‑for‑30 reverse split), with a maximum aggregate of $10.0 million, a maximum 25% discount to market, and a proposed issuance window of up to three months (extendable to six months with Nasdaq approval). The filing states the company has raised approximately $14.8 million and issued 1,054,841 shares under its ATM program and that it continues to need additional capital to maintain operations. The Board recommends voting FOR all proposals. The proxy also discloses governance details including independent committee composition and an audit committee financial expert.